{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:49:02Z","timestamp":1792788542440,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the 2020 Top Young Talents from the Central Plains and the Henan Medical Science and Technology Tackling Program Key Project","award":["SBGJ202302026"],"award-info":[{"award-number":["SBGJ202302026"]}]},{"name":"Henan Provincial Natural Science Foundation Project","award":["242300420097"],"award-info":[{"award-number":["242300420097"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Novel agents with innovative mechanisms of action were updated at the latest 2024 ASH Annual Meeting, some featuring first trials in combinations. Advances span new antibodies, bispecific T-cell engagers, next-generation CELMoDs, and agents targeting previously unexplored pathways in relapsed\/refractory multiple myeloma. Key updates include: Cevostamab (FcRH5\u00d7CD3) demonstrated a 30.2% overall response rate in patients who underwent BCMA-targeted treatment and 60.6% in BCMA-targeted na\u00efve patients;the triple-step dosing strategy reduced cytokine release syndrome. Lisaftoclax (APG-2575, BCL-2 inhibitor) displayed overall response rates ranging from 61.3 to 100% and \u2265\u2009VGPR rates of 32.3\u2013100%, supporting enhanced response depth with favorable safety in combination regimens. Inobrodib (CCS1477, p300\/CBP inhibitor) plus lenalidomide achieved a 71% overall response rate in pomalidomide-refractory patients, marking the first oral epigenetic modulator to reverse immunomodulatory drug resistance. Elranatamab (ELRA, BCMA\u00d7CD3) combined with carfilzomib and dexamethasone yielded an 83.3% overall response rate with a median duration of response not reached. Mezigdomide (MEZI, CELMoD) showed an 85.7% overall response rate and 17.5-month progression-free survival in Lenalidomide-refractory patients. ISB 2001 (BCMA\u00d7CD38\u00d7CD3 tri-specific antibody): achieved a 90% overall response rate at \u2265\u200950\u00a0\u00b5g\/kg in heavily pretreated patients, with low-grade cytokine release syndrome observed. Through multi-targeted design, reversal of drug resistance mechanisms, and optimized combination strategies, treatment approaches for relapsed\/refractory multiple myeloma are evolving toward greater precision, durability, and individualization.<\/jats:p>","DOI":"10.1186\/s40364-025-00803-0","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:02:00Z","timestamp":1751353320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Emerging therapeutic agents in multiple myeloma: highlights from the 2024 ASH annual meeting"],"prefix":"10.1186","volume":"13","author":[{"given":"Qing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quande","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"803_CR1","doi-asserted-by":"crossref","unstructured":"Zhao J, Ren Q, Liu X, Guo X, Song Y. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting. J Hematol Oncol. 2023;16(1):92.","DOI":"10.1186\/s13045-023-01489-3"},{"issue":"Suppl 1","key":"803_CR2","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.1182\/blood-2024-199519","volume":"144","author":"M Delforge","year":"2024","unstructured":"Delforge M, Richter J, Cohen YC, Corradini P, Sborov DW, Lesokhin AM, et al. Biomarker correlates and clinical activity of Cevostamab in patients with triple-class refractory multiple myeloma who have received\u2009\u2265\u20091 prior B-Cell maturation antigen (BCMA)-targeted bispecific antibody results from the phase I\/II CAMMA 2 study. Blood. 2024;144(Suppl 1):4732.","journal-title":"Blood"},{"issue":"Suppl 1","key":"803_CR3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2024-199542","volume":"144","author":"J Richter","year":"2024","unstructured":"Richter J, Thomas SK, Krishnan AY, Laubach JP, Cohen AD, Trudel S, et al. Cevostamab in patients with heavily pretreated relapsed\/refractory multiple myeloma: updated results from an ongoing phase I study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies. Blood. 2024;144(Suppl 1):1021.","journal-title":"Blood"},{"issue":"Suppl 1","key":"803_CR4","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood-2024-202713","volume":"144","author":"S Ailawadhi","year":"2024","unstructured":"Ailawadhi S, Chanan-Khan AA, Khouri J, Yannakou CK, Chen Z, Wang YY, et al. Lisaftoclax (APG-2575) combined with novel therapeutic regimens in patients with relapsed or refractory multiple myeloma or Immunoglobulin light chain (AL) amyloidosis. Blood. 2024;144(Suppl 1):1022.","journal-title":"Blood"},{"issue":"12","key":"803_CR5","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.ccell.2023.11.001","volume":"41","author":"L Nicosia","year":"2023","unstructured":"Nicosia L, Spencer GJ, Brooks N, Amaral FMR, Basma NJ, Chadwick JA, et al. Therapeutic targeting of EP300\/CBP by bromodomain Inhibition in hematologic malignancies. Cancer Cell. 2023;41(12):2136\u201353.","journal-title":"Cancer Cell"},{"issue":"Suppl 1","key":"803_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/blood-2024-199779","volume":"144","author":"E Searle","year":"2024","unstructured":"Searle E, Campbell V, Pawlyn C, Bygrave C, Gooding S, Cavet J, et al. Tolerability and clinical activity of novel first-in-class oral agent, Inobrodib (CCS1477), in combination with Pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma. Blood. 2024;144(Suppl 1):1023.","journal-title":"Blood"},{"issue":"9","key":"803_CR7","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367.","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"803_CR8","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1182\/blood-2024-210520","volume":"144","author":"MH Tomasson","year":"2024","unstructured":"Tomasson MH, Gabayan E, Ali SA, Afram G, Ghorashi S, Creel T, et al. Efficacy of Elranatamab in combination with Carfilzomib and dexamethasone in the phase 1b MagnetisMM-20 trial in relapsed or refractory multiple myeloma. Blood. 2024;144(Suppl 1):1024.","journal-title":"Blood"},{"issue":"11","key":"803_CR9","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","volume":"389","author":"PG Richardson","year":"2023","unstructured":"Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ, Ramasamy K, et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med. 2023;389(11):1009\u201322.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"803_CR10","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1182\/blood-2024-198408","volume":"144","author":"I Sandhu","year":"2024","unstructured":"Sandhu I, Richardson PG, Oriol A, White D, Leblanc R, Raje N, et al. Mezigdomide plus dexamethasone and bortezomib or Carfilzomib in patients with relapsed\/refractory multiple myeloma: updated results from the CC-92480-MM-002 trial. Blood. 2024;144(Suppl 1):1025.","journal-title":"Blood"},{"issue":"10","key":"803_CR11","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s43018-024-00821-1","volume":"5","author":"L Carretero-Iglesia","year":"2024","unstructured":"Carretero-Iglesia L, Hall OJ, Berret J, Pais D, Estoppey C, Chimen M, et al. ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells. Nat Cancer. 2024;5(10):1494\u2013514.","journal-title":"Nat Cancer"},{"issue":"Suppl 1","key":"803_CR12","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood-2024-208189","volume":"144","author":"H Quach","year":"2024","unstructured":"Quach H, Augustson B, Sia H, Shah N, Lichtman EI, Liedtke M, et al. First results of a phase 1, first-in-human, dose escalation study of ISB 2001, a BCMAxCD38xCD3 targeting tri-specific antibody in patients with relapsed\/refractory multiple myeloma. Blood. 2024;144(Suppl 1):1026.","journal-title":"Blood"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00803-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-025-00803-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00803-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:02:02Z","timestamp":1751353322000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-025-00803-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1186\/s40364-025-00803-0","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable for this summary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable for this summary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}